{"nctId":"NCT00925587","briefTitle":"Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease","startDateStruct":{"date":"2009-06"},"conditions":["Anemia","Chronic Kidney Disease"],"count":358,"armGroups":[{"label":"Q2W","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: darbepoetin alfa"]},{"label":"QM","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: darbepoetin alfa"]}],"interventions":[{"name":"darbepoetin alfa","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 18 years of age\n* Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)\n* Two consecutive screening Hb values taken at least 7 days apart must each be \\<10.0 g/dL\n* TSAT ≥ 15%\n\nExclusion Criteria:\n\n* Upper or lower GI bleeding within 6 months before enrolment\n* ESA use within 12 weeks before enrolment\n* Uncontrolled hypertension\n* Systemic haematologic disorders\n* Prior history within 12 weeks before enrollment of events including: Acute myocardial ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis, thromboembolism.\n* Grand mal seizure within 6 months prior to enrolment\n* Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5 years prior to enrolment.\n* Red blood cell transfusion within 12 weeks prior to enrolment\n* Androgen therapy within 8 weeks prior to enrolment\n* Pregnancy or breast feeding, or inadequate contraception\n* Currently receiving immunosuppressive therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)","description":"The Adjusted Analysis is the primary analysis and includes treatment group and baseline Hb value as covariates. Non-inferiority is concluded if the lower limit of the 95% confidence interval for the mean difference is above -0.5g/dL.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.157","spread":null},{"groupId":"OG001","value":"1.969","spread":null}]}]}]},{"type":"SECONDARY","title":"Achievement of Both a Hb >= 10.0 g/dL and a >= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb at Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.17","spread":"0.05"},{"groupId":"OG001","value":"9.12","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 3","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.89","spread":"0.08"},{"groupId":"OG001","value":"10.13","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 5","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.58","spread":"0.08"},{"groupId":"OG001","value":"10.28","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 7","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.90","spread":"0.09"},{"groupId":"OG001","value":"10.75","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 9","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.24","spread":"0.10"},{"groupId":"OG001","value":"10.79","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 11","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.35","spread":"0.10"},{"groupId":"OG001","value":"11.17","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 13","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.56","spread":"0.10"},{"groupId":"OG001","value":"11.05","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 15","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.42","spread":"0.11"},{"groupId":"OG001","value":"11.25","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 17","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.66","spread":"0.10"},{"groupId":"OG001","value":"11.12","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 19","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.50","spread":"0.12"},{"groupId":"OG001","value":"11.20","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 21","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.53","spread":"0.10"},{"groupId":"OG001","value":"11.09","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 23","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.36","spread":"0.09"},{"groupId":"OG001","value":"11.08","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 25","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.34","spread":"0.10"},{"groupId":"OG001","value":"10.85","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 27","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.22","spread":"0.09"},{"groupId":"OG001","value":"11.07","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 29","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.35","spread":"0.10"},{"groupId":"OG001","value":"10.90","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 31","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.31","spread":"0.09"},{"groupId":"OG001","value":"11.28","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Hb at Week 33","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.38","spread":"0.10"},{"groupId":"OG001","value":"11.15","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 1","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.65","spread":"0.10"},{"groupId":"OG001","value":"27.06","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 3","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.80","spread":"0.10"},{"groupId":"OG001","value":"27.06","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 5","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.40","spread":"0.10"},{"groupId":"OG001","value":"24.52","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 7","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.42","spread":"0.10"},{"groupId":"OG001","value":"24.52","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 9","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.01","spread":"0.10"},{"groupId":"OG001","value":"20.59","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 11","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.99","spread":"0.10"},{"groupId":"OG001","value":"20.50","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 13","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.67","spread":"0.10"},{"groupId":"OG001","value":"19.52","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 15","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.19","spread":"0.10"},{"groupId":"OG001","value":"19.15","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 17","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.71","spread":"0.10"},{"groupId":"OG001","value":"19.94","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 19","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.52","spread":"0.10"},{"groupId":"OG001","value":"19.94","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 21","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.42","spread":"0.10"},{"groupId":"OG001","value":"21.59","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 23","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.73","spread":"0.10"},{"groupId":"OG001","value":"19.98","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 25","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.55","spread":"0.10"},{"groupId":"OG001","value":"20.70","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 27","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.07","spread":"0.10"},{"groupId":"OG001","value":"20.79","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 29","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.06","spread":"0.10"},{"groupId":"OG001","value":"20.57","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose at Week 31","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.48","spread":"0.10"},{"groupId":"OG001","value":"19.39","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.21","spread":"0.10"},{"groupId":"OG001","value":"19.68","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 3","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.931","spread":"0.10"},{"groupId":"OG001","value":"1.000","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 5","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.882","spread":"0.10"},{"groupId":"OG001","value":"0.907","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 7","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.845","spread":"0.10"},{"groupId":"OG001","value":"0.907","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 9","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.724","spread":"0.10"},{"groupId":"OG001","value":"0.761","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 11","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.684","spread":"0.10"},{"groupId":"OG001","value":"0.758","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 13","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.531","spread":"0.10"},{"groupId":"OG001","value":"0.719","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 15","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.512","spread":"0.10"},{"groupId":"OG001","value":"0.707","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 17","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.459","spread":"0.10"},{"groupId":"OG001","value":"0.737","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 19","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.525","spread":"0.10"},{"groupId":"OG001","value":"0.737","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 21","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.556","spread":"0.10"},{"groupId":"OG001","value":"0.797","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 23","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":"0.10"},{"groupId":"OG001","value":"0.738","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 25","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.526","spread":"0.10"},{"groupId":"OG001","value":"0.764","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 27","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.581","spread":"0.10"},{"groupId":"OG001","value":"0.768","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 29","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.544","spread":"0.10"},{"groupId":"OG001","value":"0.762","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at Week 31","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.525","spread":"0.10"},{"groupId":"OG001","value":"0.717","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.95","spread":"0.10"},{"groupId":"OG001","value":"29.65","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)","description":"Although the endpoint is related to dose, the sample is from the Primary Analysis Set which requires a Hb value in the evaluation period","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.550","spread":"0.10"},{"groupId":"OG001","value":"0.728","spread":"0.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":175},"commonTop":["Hypertension","Oedema peripheral","Hyperkalaemia","Urinary tract infection","Diarrhoea"]}}}